Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | VDR | P11473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | G6PD | P11413 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490 | 0.88 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL66115 | 0.86 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL30862469 | 0.86 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| Water SCHEMBL3352692 | 0.86 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| SCHEMBL928195 | 0.84 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL2966008 | 0.82 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL7575512 | 0.82 | GAA (0.52) | GAACA1CA2CA12CA3 | |
| SCHEMBL11838079 | 0.81 | GAA (0.46) | GAACA1CA2CA12CA3 | |
| SCHEMBL526315 | 0.80 | GAA (0.50) | GAACA1CA2CA12CA3 | |
| SCHEMBL8073233 | 0.80 | GAA (0.50) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109313988-B | Graphene frame for supercapacitor | 加利福尼亚大学董事会 | 2023-09-05 | — | — | CN | claimed |
| US-20230241041-A1 | LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | PHARMA MAR, S.A. (ES) | 2023-08-03 | — | — | US | claimed |
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | WASHINGTON UNIVERSITY (US) | 2023-07-25 | — | — | US | claimed |
| US-11348740-B2 | Graphene frameworks for supercapacitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-31 | — | — | US | claimed |
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | WASHINGTON UNIVERSITY (US) | 2022-02-08 | — | — | US | claimed |
| US-20200294729-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3408858-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | The Regents of the University of California (US) | 2018-12-05 | — | — | EP | claimed |
| US-20170213656-A1 | GRAPHENE FRAMEWORKS FOR SUPERCAPACITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-27 | — | — | US | claimed |
| EP-2886536-A1 | Bendamustine derivatives as anti-proliferative agents | Schickaneder, Helmut (DE) | 2015-06-24 | — | — | EP | claimed |
| CN-113896607-B | Olefin oligomerization process using a catalyst comprising a chromium complex having a phosphacycle-containing ligand | 陶氏环球技术有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11891539-B2 | Cellular graphene films | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230310426-A1 | COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITOR | PHARMA MAR S.A. (ES) | 2023-10-05 | — | — | US | disclosed |
| CN-109313988-B | Graphene frame for supercapacitor | 加利福尼亚大学董事会 | 2023-09-05 | — | — | CN | disclosed |
| US-20230241041-A1 | LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | PHARMA MAR, S.A. (ES) | 2023-08-03 | — | — | US | disclosed |
| WO-1990005523-A2 | PHENANTHROLINEDICARBOXYLATE ESTERS, 4-AMINOQUINOLINE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0167901-B1 | ACTIVE COMPOUNDS | LES LABORATOIRES BEECHAM S.A. (FR) | 1990-04-04 | — | — | EP | disclosed |
| US-4876368-A | RECYCLING HEAVIER CONDENSATION PRODUCTS | HOECHST CELANESE CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| US-4853391-A | Pyrido[1,2-a]indoles and their use as cardiovascular | LABORATOIRES SOBIO SA, 13-15-25 BOULEVARD DE 1'AMIRAL BRUIX 75782 PARIS, CEDEX 16, FRANCE | 1989-08-01 | — | — | US | disclosed |
| EP-0174085-A2 | Bisarylamides of N,N'-di-[1-aminoalkyl-2]-alkylene diamines having a cardiovascular activity | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1986-03-12 | — | — | EP | disclosed |
| EP-0167901-A2 | Active compounds | LES LABORATOIRES BEECHAM S.A. (FR) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241041-A1 | LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | RXFP1, CIAPIN1, NMBR | GAA 4825/4885CA1 1441/4885CA2 2036/4885 |
| US-11242314-B2 | Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride | STX18, GPR119, SLC5A1 | GAA 268/4885CA1 881/4885CA2 818/4885 |
| US-20230310426-A1 | COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITOR | CD274, PDCD1, PDCD1LG2 | GAA 3070/4885CA1 3788/4885CA2 3891/4885 |
| US-11707538-B2 | Methods and devices to generate [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides | STX18, PFAS, FLI1 | GAA 142/4885CA1 1601/4885CA2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.